It also extends its proprietary aromatic cation technology platform to the treatment of cancer, diabetes, and other diseases.
The company’s development programs include treatments for malaria; fungal infections; tuberculosis; Pneumocystis pneumonia; and tropical diseases, including African sleeping sickness (trypanosomiasis). Immtech International is developing DB289 for treatment of African sleeping sickness, malaria, and Pneumocystis pneumonia.
The company holds worldwide patent applications, licenses, and exclusive rights to commercialize products from a library of cationic compounds to develop a pipeline of products.
Immtech was formed in 1984 and is based in Vernon Hills, Illinois.
